CD79A

Product List

Creative Biolabs is proud to offer a wide range of CD79A CART-related products, such as CAR viral particles and CAR cells.

Background

CD79a has been recognized as a particular antigen exclusive to B cells, and its expression commences during the early stages of pre-B cell formation and continues throughout B cell differentiation until reaching the plasma cell stage. This antigen, known as CD79a, holds significant importance as a crucial marker utilized in regular immunophenotypic analysis. According to studies, CD79a demonstrates a remarkable specificity of 88% and an outstanding sensitivity of 100% for B-cell differentiation.

Associated Diseases

• Acute lymphoblastic leukemia (ALL)

Anti-CD79A CAR-T Services

Anti-CD79A CAR-T In Vitro Assay Services

CD79A CAR-T Expression Test

Our extensive selection of CD79A protein and cell products are commonly employed for evaluating the expression of anti-CD79A CAR-T cells. This includes:

• CD79A protein without any conjugation
• CD79A protein biotinylated for specific applications
• CD79A protein labeled with fluorescent tags for visualization
• Custom cells engineered to overexpress CD79A

CD79A CAR-T Cytokine Release Test

CD79A CAR-T Cytokine Release Test service is a comprehensive offering that enables the accurate measurement and analysis of cytokine release in response to CD79A CART. This service utilizes advanced laboratory techniques and assays to measure the levels of various cytokines, including interleukin-6 (IL-6), interferon-gamma (IFN-γ), and tumor necrosis factor-alpha (TNF-α).

Fig.1 CAR T-cell IL-2 or IFN-γ production measured by ELISA.¹

CD79A CAR-T In Vitro Cytotoxicity Assay

We offer a comprehensive and reliable solution that provides researchers with a valuable tool for evaluating the effectiveness of CD79A CART. The assay also enables the evaluation of CD79A CAR-T cell activity by measuring various functional readouts. These readouts include target cell viability and apoptosis induction. Target cell viability can be assessed using various methods such as cell counting and MTT assay.

CD79A CAR-T Cell Proliferation Test

CD79A CAR-T Cell proliferation test is a cutting-edge and comprehensive service offered by our company. This test is specifically designed to measure the proliferation and expansion of CD79A CAR-T cells in response to different stimuli.

Anti-CD79A CAR-T In Vivo Assay Services

CD79A CAR-T Cell Therapy Animal Models

To facilitate the development and optimization of CD79A CAR-T cell therapy, animal models play a crucial role in preclinical studies. Creative Biolabs offers comprehensive animal model services to support the evaluation and efficacy testing of CD79A CAR-T cell therapy.

Fig.2 Representative flow cytometric analysis of T cells and tumor cells in bone marrow from tumor bearing mice.¹

Efficacy Test of CD79A CAR-T

The efficacy test of CD79A CAR-T is a vital step in assessing the effectiveness and potential therapeutic benefits of this innovative treatment. The efficacy test aims to evaluate the ability of CD79A CAR-T cells to effectively recognize and destroy cancer cells expressing CD79A. This test is performed in vivo to comprehensively assess the treatment's efficacy on multiple levels.

Survival of mice

Fig.3 Survival of mice from 2 independent experiments.¹

Toxicity Evaluation of CD79A CAR-T

The toxicity evaluation service at Creative Biolabs includes several assessments to comprehensively evaluate the safety profile of CD79A CAR-T cells using animal models. This includes monitoring the general health status, body weight, and any signs of distress or adverse reactions.

Reference

1. Leung, Isabel, et al. "Compromised antigen binding and signaling interfere with bispecific CD19 and CD79a chimeric antigen receptor function." Blood Advances 7.12 (2023): 2718-2730.